Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
A ?Real World? Trial to determine efficacy and health outcomes of TOUJEO compared to ?standard of care? basal insulin in patients already using basal insulin. Ensayo "mundo real" para detarminar la eficacia y los resultados de salud de Toujeo® en comparación con las insulinas del tratamiento basal estándar en pacientes ya tratados con insulina basal
To demonstrate non-inferiority of Toujeo versus ?standard of care? basal insulin therapy as measured by glycated hemoglobin (HbA1c) change. Demostrar la no inferioridad de Toujeo frente a un tra...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Rt
Update Il y a 4 ans
Kiegészítő zolpidem kezelés friss antidepresszáns kezelés alatt álló disztimiás vagy depressziós betegek alvászavarának kezelésében
A vizsgálat célja annak igazolása, hogy Stilnox antidepresszáns kezeléssel együttesen alkalmazva hatékonyabb a depresszió és disztimia okozta secunder insomnia kezelésében a betegség akut fázisában, m...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-aventis
Update Il y a 4 ans
Safety and Efficacy of Cabazitaxel in Pediatric Patients with Refractory Solid Tumors Including Central Nervous System Tumors
Phase 1 Part: To determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of cabazitaxel as a single agent in pediatric patients with recurrent or refractory solid tumors ...
Country
None
organs
None
Specialty
None
More information
Woman
Between 18 years and 75 years
Sanofi
Update Il y a 4 ans
Sanofi-Aventis EFC10073 : Essai de phase 2 randomisé évaluant larotaxel ou docétaxel associer ou non avec trastuzumab, chez des patientes ayant un cancer du sein. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Study of Larotaxel 90mg/m<sup>2</sup> or Docetaxel Every 3 Weeks, Alone or With Trastuzumab According to Her2neu Status, After Combination of Anthracycline and Cyclophosphamide as Preoperative Therapy...
Country
France
organs
Sein
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
Sanofi-Aventis VENICE : Essai de phase 3 randomisé, en double aveugle évaluant l’efficacité et la tolérance de l’aflibercept, chez des patients ayant un cancer de la prostate métastatique, non sensible aux androgènes, traité par docétaxel et prednisone. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité d’un traitement associant l’aflibercept au docétaxel et prednisone, chez des patients ayant un cancer de la prostate métastatique, non sensible aux a...
Country
France
organs
Prostate
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
A phase III randomized, double-blind, active-comparator controlled clinical trial to study the safety, tolerability, and immunogenicity of V419 in healthy infants when given at 2, 4, and 11 to 12 months
To evaluate the immunogenicity of PR5I when given at 2, 4, and 11 to 12 months of age.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-Origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Adult and Elderly subjects
• To describe the immune response of each candidate vaccine 21 days after each vaccination by hemagglutination inhibition (HAI) and seroneutralization (SN) method in all adult and elderly subjects. • ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Research
Update Il y a 4 ans
A randomisation, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of SR121463B in patients with syndrome of inappropriate antidiuretic hormone secretion
Evaluar la eficacia de SR121463B en la corrección de hiponatremia en pacientes con SIADH
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
A clinical trial to study the antibody response and tolerability of GARDASIL®9 in women aged 27 to 45 years old compared to women aged 16 to 26 years old
To demonstrate that the administration of GARDASIL®9 in 27- to 45 year old women induces non inferior geometric mean titres (GMTs) for serum anti-HPV 16, 18, 31, 33, 45, 52, and 58 compared with 16- t...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated with Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent Καμπαζιταξέλη έναντι της αλλαγής σε εναλακτικό παράγοντα που στοχεύει στον υποδοχέα των ανδρογόνων (AR) (αμπιρατερόνη ή ενζαλουταμίδη) σε ασθενείς με μεταστατικό ευνουχοάντοχο καρκίνο του προστάτη (mCRPC) που έλαβαν στο παρελθόν θεραπεία με δοσεταξέλη και στους οποίους απέτυχε γρήγορα προηγούμενη θεραπεία με παράγοντα που στοχεύει στον AR
To compare the radiographic progression-free survival (rPFS) of chemotherapy (cabazitaxel plus prednisone, Arm A) versus AR-targeted therapy (enzalutamide or abiraterone acetate plus prednisone, Arm B...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
6
7
8
9
10
11
12
13
14
15
Next